[Research and developmental strategy of anti-dyslipidemic agents].
Tanimoto
Tatsuo
T
tatsuo@sankyo.co.jp
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000037:antagonists & inhibitors; D000818:Animals; D016632:Apolipoprotein A-I / Q000097:blood; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control; D004195:Disease Models, Animal; D015195:Drug Design; D013186:Farnesyl-Diphosphate Farnesyltransferase / Q000037:antagonists & inhibitors; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000209:etiology; D000960:Hypolipidemic Agents; D020320:Oligoribonucleotides, Antisense; D011341:Probucol / Q000031:analogs & derivatives; D043562:Receptors, G-Protein-Coupled / Q000819:agonists; D011978:Receptors, Nicotinic
D016632:Apolipoprotein A-I; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; C473653:HCAR3 protein, human; D000960:Hypolipidemic Agents; D020320:Oligoribonucleotides, Antisense; D043562:Receptors, G-Protein-Coupled; D011978:Receptors, Nicotinic; C106092:microsomal triglyceride transfer protein; D013186:Farnesyl-Diphosphate Farnesyltransferase; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; C471047:succinobucol; D011341:Probucol